JP2019514979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514979A5 JP2019514979A5 JP2018558293A JP2018558293A JP2019514979A5 JP 2019514979 A5 JP2019514979 A5 JP 2019514979A5 JP 2018558293 A JP2018558293 A JP 2018558293A JP 2018558293 A JP2018558293 A JP 2018558293A JP 2019514979 A5 JP2019514979 A5 JP 2019514979A5
- Authority
- JP
- Japan
- Prior art keywords
- inflammatory
- lipid
- pharmaceutical composition
- rofleponide
- purine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 claims 23
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 19
- 230000003110 anti-inflammatory effect Effects 0.000 claims 15
- 239000002105 nanoparticle Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical group C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 claims 11
- 229950004432 rofleponide Drugs 0.000 claims 11
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 6
- 229960004436 budesonide Drugs 0.000 claims 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims 5
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- 102000014702 Haptoglobin Human genes 0.000 claims 2
- 108050005077 Haptoglobin Proteins 0.000 claims 2
- 229930182558 Sterol Natural products 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims 2
- 229940049918 linoleate Drugs 0.000 claims 2
- 229940105132 myristate Drugs 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 150000003432 sterols Chemical class 0.000 claims 2
- 235000003702 sterols Nutrition 0.000 claims 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- LRFJOIPOPUJUMI-KWXKLSQISA-N 2-[2,2-bis[(9z,12z)-octadeca-9,12-dienyl]-1,3-dioxolan-4-yl]-n,n-dimethylethanamine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC1(CCCCCCCC\C=C/C\C=C/CCCCC)OCC(CCN(C)C)O1 LRFJOIPOPUJUMI-KWXKLSQISA-N 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- NRLNQCOGCKAESA-KWXKLSQISA-N [(6z,9z,28z,31z)-heptatriaconta-6,9,28,31-tetraen-19-yl] 4-(dimethylamino)butanoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCC(OC(=O)CCCN(C)C)CCCCCCCC\C=C/C\C=C/CCCCC NRLNQCOGCKAESA-KWXKLSQISA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940070765 laurate Drugs 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 230000000770 proinflammatory effect Effects 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 229940070710 valerate Drugs 0.000 claims 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021212753A JP2022058438A (ja) | 2016-05-09 | 2021-12-27 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333574P | 2016-05-09 | 2016-05-09 | |
| US62/333,574 | 2016-05-09 | ||
| US201662359429P | 2016-07-07 | 2016-07-07 | |
| US62/359,429 | 2016-07-07 | ||
| US201762449623P | 2017-01-24 | 2017-01-24 | |
| US62/449,623 | 2017-01-24 | ||
| PCT/EP2017/060891 WO2017194454A1 (en) | 2016-05-09 | 2017-05-08 | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212753A Division JP2022058438A (ja) | 2016-05-09 | 2021-12-27 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514979A JP2019514979A (ja) | 2019-06-06 |
| JP2019514979A5 true JP2019514979A5 (enExample) | 2020-06-18 |
| JP7066632B2 JP7066632B2 (ja) | 2022-05-13 |
Family
ID=58671696
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558293A Active JP7066632B2 (ja) | 2016-05-09 | 2017-05-08 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
| JP2021212753A Withdrawn JP2022058438A (ja) | 2016-05-09 | 2021-12-27 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021212753A Withdrawn JP2022058438A (ja) | 2016-05-09 | 2021-12-27 | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11458106B2 (enExample) |
| EP (1) | EP3454835B1 (enExample) |
| JP (2) | JP7066632B2 (enExample) |
| CN (1) | CN109152735B (enExample) |
| ES (1) | ES2871537T3 (enExample) |
| WO (1) | WO2017194454A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| WO2018081480A1 (en) * | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2017194454A1 (en) | 2016-05-09 | 2017-11-16 | Astrazeneca Ab | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| US11820728B2 (en) | 2017-04-28 | 2023-11-21 | Acuitas Therapeutics, Inc. | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| JP7355731B2 (ja) | 2017-08-16 | 2023-10-03 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤における使用のための脂質 |
| JP7461872B2 (ja) | 2017-08-17 | 2024-04-04 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤における使用のための脂質 |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| EP3852911B1 (en) | 2018-09-21 | 2025-01-22 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| PL3908568T3 (pl) | 2019-01-11 | 2024-12-02 | Acuitas Therapeutics, Inc. | Lipidy do dostarczania środków czynnych w nanocząstkach lipidowych |
| CN114173826A (zh) * | 2019-05-08 | 2022-03-11 | 阿斯利康(瑞典)有限公司 | 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物 |
| CN110974954B (zh) * | 2019-12-24 | 2021-03-16 | 珠海丽凡达生物技术有限公司 | 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法 |
| KR20230002300A (ko) * | 2020-01-21 | 2023-01-05 | 이더알엔에이 이뮤노테라피스 엔브이 | 지질 나노입자 |
| KR20230051172A (ko) | 2020-07-16 | 2023-04-17 | 아퀴타스 테라퓨틱스 인크. | 지질 나노 입자에 사용하기 위한 양이온성 지질 |
| EP4370134A4 (en) | 2021-07-13 | 2025-08-06 | Technion Res & Dev Foundation | COMPOSITIONS AND METHODS FOR TREATING A HEALTH CONDITION |
| AU2022382676B2 (en) * | 2021-11-05 | 2026-04-02 | G2Gbio, Inc. | Pharmaceutical kit for parenteral co-administration |
| WO2023114943A2 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2023148303A1 (de) * | 2022-02-02 | 2023-08-10 | Mslsolutions Gmbh | Verfahren zur medikament- und impfstoffherstellung |
| CN114617980A (zh) * | 2022-03-09 | 2022-06-14 | 广州国家实验室 | 可电离脂质纳米颗粒及其应用 |
| EP4648754A1 (en) * | 2023-01-09 | 2025-11-19 | Northmirs, Inc. | Microrna-based particle for the treatment of dysregulated immune response |
| WO2025215636A1 (en) | 2024-04-08 | 2025-10-16 | Yeda Research And Development Co. Ltd. | Anti-defense system polypeptides and uses thereof |
| WO2026009227A1 (en) | 2024-07-04 | 2026-01-08 | Yeda Research And Development Co. Ltd. | Compositions for downregulating zeb2 in macrophages and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA95160463B1 (ar) * | 1994-12-22 | 2005-10-04 | استرا أكتيبولاج | مساحيق للاستنشاق |
| WO2006031471A2 (en) * | 2004-09-01 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Liposomal vectors |
| CN101708338B (zh) | 2008-12-26 | 2014-06-04 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 含甾体结构的前药及其高度分散制剂 |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| NZ597504A (en) * | 2009-06-15 | 2013-10-25 | Alnylam Pharmaceuticals Inc | Lipid formulated dsrna targeting the pcsk9 gene |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制 |
| CN103442700B (zh) * | 2011-03-24 | 2016-04-06 | 利奥制药有限公司 | 含有脂质纳米颗粒和皮质类固醇或维生素d衍生物的组合物 |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| ES2923757T3 (es) * | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| EP2638896A1 (en) * | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| CN105307641A (zh) | 2013-05-03 | 2016-02-03 | 西莱克塔生物科技公司 | 用于降低不期望体液免疫应答的给药组合 |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2017194454A1 (en) | 2016-05-09 | 2017-11-16 | Astrazeneca Ab | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
-
2017
- 2017-05-08 WO PCT/EP2017/060891 patent/WO2017194454A1/en not_active Ceased
- 2017-05-08 JP JP2018558293A patent/JP7066632B2/ja active Active
- 2017-05-08 US US15/589,181 patent/US11458106B2/en active Active
- 2017-05-08 ES ES17721707T patent/ES2871537T3/es active Active
- 2017-05-08 CN CN201780026989.5A patent/CN109152735B/zh active Active
- 2017-05-08 EP EP17721707.2A patent/EP3454835B1/en active Active
-
2021
- 2021-12-27 JP JP2021212753A patent/JP2022058438A/ja not_active Withdrawn
-
2022
- 2022-08-02 US US17/879,362 patent/US20220370370A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220370370A1 (en) | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof | |
| JP7275111B2 (ja) | 脂質ナノ粒子の生成方法 | |
| JP6924744B2 (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| Zadeh Mehrizi et al. | Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: real-time PCR assay plus | |
| EP3448393A1 (en) | Novel complexes of immunostimulatory compounds, and uses thereof | |
| JP2015515992A5 (enExample) | ||
| HRP20200117T1 (hr) | Nukleinske kiseline koje se vežu na sdf-1 i njihova upotreba | |
| JP2012067116A5 (enExample) | ||
| JP2017509690A5 (enExample) | ||
| Hong et al. | Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus | |
| Li et al. | The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid | |
| Liu et al. | Targeted delivery of macrophage membrane biomimetic liposomes through intranasal administration for treatment of ischemic stroke | |
| Liu et al. | Low-dose mildronate-derived lipidoids for efficient mRNA vaccine delivery with minimal inflammation side effects | |
| Monroe et al. | Harnessing nanostructured systems for improved treatment and prevention of HIV disease | |
| WO2017092230A1 (zh) | 双黄酮化合物及其治疗癌症和制备药物的用途 | |
| JP2006508912A5 (enExample) | ||
| CN102429897B (zh) | 一种提高桑色素口服生物利用度的药物组合物 | |
| CN101805285B (zh) | 含烟酸姜黄素酯衍生物及其制造方法和用途 | |
| WO2024150222A1 (en) | Ionizable lipids and nanoparticles comprising same | |
| JP2023526707A (ja) | カバジタキセル弱塩基性誘導体およびその製剤 | |
| CN103690482B (zh) | 以磷脂复合物为中间体的甘草酸自乳化制剂用浓缩液及制备方法 | |
| CN102115484B (zh) | 一种两性霉素b降解产物、其制备方法及其应用 | |
| CN106133024B (zh) | 用于疏水性药物递送的新颖的基于聚合物的助水溶物 | |
| CN102847164A (zh) | 蚕蛹油在提高小分子药物生物利用度中的用途 | |
| Kita et al. | PB01: a recombinant human follistatin protein for the treatment of neutrophilic lung diseases |